

1 Research Article.

2 **Is 7-days home BP measurement comparable to 24-hours Ambulatory BP Measurement?**

3 Sheikh Mohammed Shariful Islam, Chandan Karmakar, Imran Ahmed, Ralph Maddison

4 Correspondence: shariful.islam@deakin.edu.au

5

6 **ABSTRACT**

7 High blood pressure (BP) or hypertension is a significant risk factor for the global burden of
8 cardiovascular diseases. Home blood pressure measurements (HBPM) have been
9 recommended for hypertension diagnosis, treatment initiation and medication titration, but
10 guidelines for the number of measurements and duration are inconsistent. This study compared
11 the accuracy of 3 home BP measurements per day for seven days with 24-hour ambulatory BP
12 measurements. We examined 24-hour ambulatory BP measurements (ABPM) and HBPM
13 during-morning, afternoon, and evening each day for seven days in healthy community living
14 volunteers. Standardized Bland-Altman scatterplots and limits of agreement (LOA) were used to
15 assess absolute reliability and the variability of measurement biases. We used nonparametric
16 Mann-Whitney U-tests to compare the mean (SD) of the devices. Correlations between HBPM
17 and 24-hour ABPM measurements were statistically significant at $p < 0.05$. The high correlation
18 coefficient ($r = 0.75$) was observed between the systolic BP retrieved from two devices compared
19 to moderate correlation ($r = 0.46$) among diastolic BP. A significant difference was found for
20 systolic BP ($P < 0.05$) between the HBPM and ABPM but was non-significant for diastolic BP
21 ($P > 0.05$). In Bland-Altman plots, the LOA between HBPM and ABPM was 0.07-26.23 mmHg for
22 SBP and 11.24 -16.20 mmHg for DBP. The overall mean difference (bias) in SBP and DBP was
23 13.08 and 2.48, respectively. Our results suggest that HBPM three times per day for seven days
24 can potentially be used where ABPM is unavailable. Further studies in a diverse group of people
25 with hypertension are needed.

26

27 **Wordcount:** Abstract-243; Text-1550; References-16; Figures-1; (Supplementary Tables-1,
28 Supplementary Figures 2)

29

30 **Introduction**

31 High blood pressure (BP) or hypertension is the leading contributor of cardiovascular morbidity
32 and mortality with increasing prevalence; it accounted for 10.4 million deaths globally in 2017
33 [1]. A recent campaign screening 1.2 million people in 80 countries found almost 40% of people
34 with hypertension were unaware of their condition, and only 33.2% had their BP controlled [1].
35 Further, high BP variability is associated with poor cardiovascular outcomes independent of the
36 level of BP [2]. High BP is associated with several adverse health outcomes, including stroke,
37 chronic kidney diseases, diabetes complications, among others [3, 4].

38

39 Despite the importance of BP control, lack of timely diagnosis, monitoring and adequate
40 treatment of BP remains challenging worldwide [5]. BP undergoes marked variation over 24-
41 hours and often remains asymptomatic in many people. Therefore, traditional BP measurement
42 at clinics might leave a significant portion of people with potential high BP undiagnosed. Multiple
43 office visits at different timepoints and measurements by expert health care professionals are
44 required to diagnose hypertension, which is impractical for many people. Ambulatory BP
45 measurement (ABPM) is recognized as the reference standard for hypertension detection but is
46 often intrusive, cumbersome for extended use and costlier than current methods [6]. In contrast,
47 home BP measurements (HBPM) performed under a specific protocol using validated
48 equipment can overcome many barriers, such as ruling out white coat hypertension, masked
49 hypertension and record BP changes over time [7].

50

51 HBPM is an effective means for detecting hypertension and is more closely associated with
52 hypertension-induced organ damage and adverse cardiovascular outcomes [8]. Several studies

53 have compared HBPM with ABPM and clinic BP, which have highlighted the potential of HBPM
54 as means for hypertension detection and treatment decisions [3, 9-11]. However, there is
55 currently no recommendation for the number of measurements or period of follow-up required
56 each day for HBPM to establish it as a feasible alternative to ABPM. To address this gap, we
57 aimed to determine the comparability of 3 home BP measurements per day at home over seven
58 days with 24-hour ambulatory BP measurement.

59

60 **Methods**

61 A convenience sample of 20 healthy adult volunteers was recruited via advertisements at the
62 Deakin University Burwood Campus, Melbourne, Australia. Participants were selected from
63 community settings and attendees at general practice clinics in Melbourne. All participants had
64 normal BP (<130/90 mmHg) at enrollment, were willing to wear an ambulatory BP device for 24-
65 hours and record home BP measurement three times a day for the next seven days. We
66 excluded those taking antihypertensive medications, had severe debilitating diseases, limited
67 mobility, and known mental disorders. The study protocol was approved by the Deakin
68 University Faculty of Health Human Ethics Advisory Group (HEAG-H 135_2017).

69

70 We used an ABPM device (A & D Medical Corp, TM-2430) with an adult cuff size to obtain 24-
71 hour BP readings. The ABPM device was programmed to record BP every 30 minutes during 16
72 hours of that day and every 60 minutes during the remaining 8 hours at night. We provided
73 study participants with a validated home BP device (Omron HEM 7121). They were requested
74 to take BP measurements three times each day during-morning, afternoon, and evening using
75 the provided device and record values using a log sheet. Participants were educated regarding
76 the proper use of each device and how to complete the log sheet. After seven days, all records
77 were collected for data entry and analysis.

78

79 The primary outcome of this study was the mean difference between 24-hours ABPM and
80 HBPM measurements for seven days. Data were presented as mean, SD (standard deviation),
81 and range. The mean HBPM measurements were compared against corresponding reference
82 ABPM values. Extreme values were manually investigated to rule out possible measurement
83 errors. As the data did not differ significantly, we used the entire dataset from all devices in
84 these analyses. Pearson product-moment correlation coefficients were estimated. Data were
85 explored graphically using box plots and scatter plots to determine the agreement between the
86 two measurements. Standardized Bland-Altman scatterplots and limits of agreement (LOA)
87 were used to assess absolute reliability and the variability of measurement biases across the
88 measurement range. We used nonparametric Mann-Whitney U tests to compare the mean (SD)
89 of the devices and measure the *P-value* for Box plot analysis. MATLAB 2017a software was
90 used to perform data analyses.

91

92 **Results**

93 After seven days of home BP and 24-hour ABPM measurement, we collected 840 and 1530 BP
94 measurements from the respective devices. The majority of participants were young with a
95 mean age of 20.4 (\pm 5.4) years, highly educated (65% university graduate), employed (60%),
96 and equal participation from both sexes. Mean baseline BP was 112/74 mm Hg. Overall
97 participant characteristics are presented in Table 1.

98

99 The mean systolic and diastolic values of HBPM and 24-hour ABPM were similar. The
100 correlations between HBPM and 24-hour ABPM measurements were statistically significant at
101 $p < 0.05$. A high Pearson product-moment correlation coefficient ($r = 0.75$) was observed for the
102 systolic BP retrieved from two devices compared to moderate correlation ($r = 0.46$) for diastolic
103 BP (Supplementary Figure 1). A significant difference was found for systolic BP ($P < 0.05$)
104 between the HBPM and ABPM, but this difference was non-significant for diastolic BP ($P > 0.05$).

105

106 The Box plot (Figure 1) and the Bland-Altman plots for systolic and diastolic measurements by
107 ABPM and HBPM revealed no systematic biases. LOA between HBPM and ABPM devices was
108 0.07-26.23 mm Hg for SBP and 11.24 -16.20 mm Hg for DBP. The overall mean difference
109 (bias) in SBP and DBP was 13.08 and 2.48, respectively (Supplementary Figure 2). Overall, for
110 the ABPM device, the mean (SD) systolic and diastolic BP was 125.08 (9.86) mmHg and 73.87
111 (6.31) mmHg, respectively. For the Home BP device, the mean (SD) systolic and diastolic BP
112 was 112.00 (8.76) mmHg and 71.39 (7.25) mmHg.

113

114 **Discussion**

115 In this study, we assessed whether a pre-specified home BP measurement strategy provided
116 reliable estimates of BP compared to 24-hours ABPM, the gold standard for detecting
117 hypertension and treatment initiation. Our results suggest that HBPM measurements three
118 times per day for seven days could be an alternative approach to detect hypertension, monitor
119 BP and optimize treatment where ABPM is unavailable or impractical.

120

121 BP is an important marker of cardiovascular health and can be measured and monitored by
122 participants in their homes using commercially available HBPM devices. The 2017 American
123 College of Cardiology, the US Preventive Services Task Force and most recent 2020
124 International Society of Hypertension Global Hypertension Practice Guidelines recommend
125 obtaining out-of-clinic BP measurements to confirm the diagnosis of hypertension before
126 initiating treatment [4, 11, 12]. A study by Bello et al. reported the use of HBPM to estimate
127 home BP reliably and out-of-clinic hypertension diagnosis [8]. The study suggested an average
128 of morning and evening readings of 3 days of HBPM but did not validate the findings against an
129 ABPM. Another study comparing HBPM with automated clinic BP showed that HBPM was much
130 higher compared to clinic BP.

131
132 Although HBPM is widely recommended, currently, there is no consensus regarding the
133 recommended number of measurements in a day and follow-up period required to diagnose
134 hypertension compared to ABPM. Previous systematic reviews reported differences in the
135 number of days, readings each day and timings needed to diagnose BP [10, 13]. Bello et al.
136 suggested HBPM using the average of morning and evening readings for three days but
137 compared HBPM with office BP only [8]. Our results correlate with previous studies showing
138 good reliability and agreement between HBPM and ABPM [3, 14, 15]. Other studies have
139 reported negligible or no agreement between ABPM and HBPM [9, 16]. These differences might
140 be due to the different methods of obtaining HBPM measurements, using different devices,
141 population groups, and analysis methods. Our participants were relatively young, employed,
142 and probably had high physical activity compared to previous studies.

143
144 HBPM is easy to perform, less burdensome, and cheapest among all BP measurement
145 methods. Our data showed that HBPM performed well compared to ABPM. Current clinic BP
146 measuring techniques are vulnerable to the white coat hypertension phenomena and masked
147 hypertension, resulting in overuse or underuse of medication. In contrast, there are several
148 barriers to the widespread adoption of ABPM in regular clinical practice, specifically in resource-
149 poor settings, rural and remote areas. Therefore, it might be more practical in clinical practise to
150 encourage participants to monitor their BP at home three times per day for a week and report
151 the findings during a consultation. The approach might help clinicians improve hypertension
152 diagnosis and monitor medication effectiveness and titration for optimum BP control. Further,
153 newer internet-enabled HBPM devices enable reporting BP changes more accurately and
154 integrate with clinic record systems providing better BP management insights.

155

156 A significant strength of this study was the comparison of HBPM against ABPM in healthy young
157 adults. Our study had few potential limitations. We did not record the exact time point of home
158 BP measurements and activities performed before measurement, which could bias the reports.
159 Participants measured BP three times (morning, evening and night) at their convenience. Our
160 sample size was small, relatively young and non-hypertensive; therefore, the results need to be
161 interpreted with caution. Further research comparing different HBPM devices and approaches in
162 diverse population groups is recommended.

163

164 **Conclusion**

165 HBPM measurements three times per day for seven days could be an alternative approach to
166 detect and manage hypertension; however, further studies are recommended in diverse groups
167 with hypertension. This approach could be helpful in low-resource settings where ABPM is not
168 feasible.

169

170 **Declaration**

171 Ethics approval and consent to participate: All participants provided written informed consent
172 prior to data collection. The study protocol was approved by the Deakin University Faculty of
173 Health Human Ethics Advisory Group (HEAG-H 135_2017).

174 Consent for publication: All authors provided consent for publication.

175 Availability of data and materials: Data are available in an open access server [17]

176 (<https://data.jmir.org/2020/1/e22436/authors>)

177 Competing interests: The authors declare no competing interests.

178 Funding: SMSI is funded by the National Heart Foundation of Australia and NHMRC

179 Emerging Leadership Fellowship

180 Authors' contributions: Concept: SMSI; Data collection: SMSI; Data analysis: CK; Funding:

181 SMSI; Drafting: SMSI and IA; Critical review: SMSI and RM.

182 Acknowledgements: We thank the participants for their valuable time for this research.

183 **Conflict of interest**

184

185 REFERENCES

- 186 1. Poulter NR, Borghi C, Burger D, Castillo RR, Damasceno A, Ito S, Jose AP, Kruger R, Morgan T,
187 Nilsson PM *et al*: **May Measurement Month 2018: results of blood pressure screening from 41**
188 **countries**. *European Heart Journal Supplements* 2020, **22**(Supplement_H):H1-H4.
- 189 2. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR:
190 **Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and**
191 **episodic hypertension**. *The Lancet* 2010, **375**(9718):895-905.
- 192 3. O'brien E, Asmar R, Beilin L, Imai Y, Mallion J-M, Mancia G, Mengden T, Myers M, Padfield P,
193 Palatini P: **European Society of Hypertension recommendations for conventional, ambulatory**
194 **and home blood pressure measurement**. *Journal of hypertension* 2003, **21**(5):821-848.
- 195 4. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M,
196 Stergiou GS, Tomaszewski M *et al*: **2020 International Society of Hypertension Global**
197 **Hypertension Practice Guidelines**. *Hypertension* 2020, **75**(6):1334-1357.
- 198 5. Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, Gregg EW, Bennett JE,
199 Solomon B, Singleton RK: **Worldwide trends in hypertension prevalence and progress in**
200 **treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative**
201 **studies with 104 million participants**. *The Lancet* 2021.
- 202 6. Parati G, Stergiou G, O'Brien E, Asmar R, Beilin L, Biló G, Clement D, De La Sierra A, De Leeuw P,
203 Dolan E: **European Society of Hypertension practice guidelines for ambulatory blood pressure**
204 **monitoring**. *Journal of hypertension* 2014, **32**(7):1359-1366.
- 205 7. Parati G, Stergiou GS, Asmar R, Biló G, De Leeuw P, Imai Y, Kario K, Lurbe E, Manolis A, Mengden
206 T: **European Society of Hypertension practice guidelines for home blood pressure monitoring**.
207 *Journal of human hypertension* 2010, **24**(12):779-785.
- 208 8. Bello NA, Schwartz JE, Kronish IM, Oparil S, Anstey DE, Wei Y, Cheung YKK, Muntner P, Shimbo
209 D: **Number of measurements needed to obtain a reliable estimate of home blood pressure:**
210 **results from the improving the detection of hypertension study**. *Journal of the American Heart*
211 *Association* 2018, **7**(20):e008658.
- 212 9. Park J-S, Rhee M-Y, Namgung J, Lee SY, Cho D-K, Choi T-Y, Kim SY, Kim JY, Park SM, Choi JH:
213 **Comparison of optimal diagnostic thresholds of hypertension with home blood pressure**
214 **monitoring and 24-hour ambulatory blood pressure monitoring**. *American Journal of*
215 *Hypertension* 2017, **30**(12):1170-1176.
- 216 10. Verberk WJ, Kroon AA, Kessels AG, de Leeuw PW: **Home blood pressure measurement: a**
217 **systematic review**. *Journal of the American College of Cardiology* 2005, **46**(5):743-751.
- 218 11. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, DePalma SM, Gidding
219 S, Jamerson KA, Jones DW: **2017**
220 **ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention,**
221 **detection, evaluation, and management of high blood pressure in adults: a report of the**
222 **American College of Cardiology/American Heart Association Task Force on Clinical Practice**
223 **Guidelines**. *Journal of the American College of Cardiology* 2018, **71**(19):e127-e248.
- 224 12. Siu AL: **Screening for high blood pressure in adults: US Preventive Services Task Force**
225 **recommendation statement**. *Annals of internal medicine* 2015, **163**(10):778-786.

- 226 13. Piper MA, Evans CV, Burda BU, Margolis KL, O'Connor E, Whitlock EP: **Diagnostic and predictive**
227 **accuracy of blood pressure screening methods with consideration of rescreening intervals: a**
228 **systematic review for the US Preventive Services Task Force.** *Annals of internal medicine* 2015,
229 **162(3):192-204.**
- 230 14. Mutlu S, Sari O, Arslan E, Aydogan U, Doganer YC, Koc B: **Comparison of ambulatory blood**
231 **pressure measurement with home, office and pharmacy measurements: is arterial blood**
232 **pressure measured at pharmacy reliable?** *J Eval Clin Pract* 2016, **22(1):40-45.**
- 233 15. Hond ED, Celis H, Fagard R, Keary L, Leeman M, O'Brien E, Vandenhoven G, Staessen JA,
234 investigators obotT: **Self-measured versus ambulatory blood pressure in the diagnosis of**
235 **hypertension.** *Journal of Hypertension* 2003, **21(4):717-722.**
- 236 16. Juhanoja EP, Niiranen TJ, Johansson JK, Puukka PJ, Jula AM: **Agreement between ambulatory,**
237 **home, and office blood pressure variability.** *Journal of hypertension* 2016, **34(1):61-67.**
- 238 17. Islam SMS, Maddison R: **A Comparison of Blood Pressure Data Obtained From Wearable,**
239 **Ambulatory, and Home Blood Pressure Monitoring Devices: Prospective Validation Study.**
240 *JMIR Data* 2020, **1(1):e22436.**

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255


256 **Table 1. Characteristics of the study participants**

Characteristics	Study participants (n=20)
Male, %	50%
Age in years, mean (SD); range	20.3 (5.4); 37.2 - 18.5
BMI ^a , mean (SD); range	23.6 (3.3); 19.9 - 25.9
Married/Living with partner, %	40%
Education (Masters or above)	65%
Employment (Fulltime) %	60%
Baseline Systolic BP, mean (SD); range	112.35 (9.79); 95 - 131
Baseline Diastolic BP, mean (SD); range	73.75 (9.14); 47- 96

257 ^aBMI: body mass index.

258

259



260

261 **Figure 1: Bland-Altman plots for mean BP measured by ambulatory vs home device**